Detalhe da pesquisa
1.
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
Hematol Oncol
; 42(1): e3222, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740931
2.
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Cancers (Basel)
; 16(5)2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473278
3.
Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(11): 1335-1344, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34109764
4.
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Clin Transl Sci
; 14(1): 373-381, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33048456
5.
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(11): 775-784, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551886
6.
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
J Clin Oncol
; 39(32): 3602-3612, 2021 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388020